Collins Helen Louise: insider trades.
Collins Helen Louise reported 13 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($808K), across 1 company.
- Transactions
- 13
- Purchases (P)
- 0
- Sales (S)
- 10
- Companies
- 1
- Name as filed
- Collins Helen Louise
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | Officer · CHIEF MEDICAL OFFICER | 13 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-17 | Enliven Therapeutics, Inc. | S | 1,844 | $50.71 | 25,240 | Form 4 |
| 2026-09-17 | Enliven Therapeutics, Inc. | S | 2,916 | $50.03 | 27,084 | Form 4 |
| 2026-09-17 | Enliven Therapeutics, Inc. | M | 5,000 | $2.48 | 30,000 | Form 4 |
| 2026-09-17 | Enliven Therapeutics, Inc. | S | 240 | $51.48 | 25,000 | Form 4 |
| 2026-08-17 | Enliven Therapeutics, Inc. | S | 3,900 | $58.37 | 26,100 | Form 4 |
| 2026-08-17 | Enliven Therapeutics, Inc. | M | 5,000 | $2.48 | 30,000 | Form 4 |
| 2026-08-17 | Enliven Therapeutics, Inc. | S | 1,100 | $59.35 | 25,000 | Form 4 |
| 2026-07-17 | Enliven Therapeutics, Inc. | S | 2,063 | $52.39 | 27,247 | Form 4 |
| 2026-07-17 | Enliven Therapeutics, Inc. | S | 2,184 | $53.42 | 25,063 | Form 4 |
| 2026-07-17 | Enliven Therapeutics, Inc. | S | 63 | $53.92 | 25,000 | Form 4 |
| 2026-07-17 | Enliven Therapeutics, Inc. | M | 5,000 | $2.48 | 30,000 | Form 4 |
| 2026-07-17 | Enliven Therapeutics, Inc. | S | 231 | $50.05 | 29,769 | Form 4 |
| 2026-07-17 | Enliven Therapeutics, Inc. | S | 459 | $51.55 | 29,310 | Form 4 |
Questions
What stock did Collins Helen Louise buy or sell?
Collins Helen Louise reported 13 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($808K), across 1 company.
Is Collins Helen Louise the same person as other filers with this name?
This page covers SEC CIK 1701247 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/collins-helen-louise-1701247.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.